Form 4: Aerovate Therapeutics Director, Habib J Dable, Acquires Stock Options in Lieu of Cash Compensation

Habib J Dable, a director of Aerovate Therapeutics, acquired stock options in lieu of cash compensation on March 4, 2024.

Summary

• On March 4, 2024, Habib J Dable, a director of Aerovate Therapeutics, Inc., was granted stock options for 1,531 shares of common stock.
• The options were awarded in lieu of cash compensation, as per the Issuer's Non-Employee Director Compensation Policy.
• The exercise price of the options is $22.49.
• The options vest in four equal installments, starting March 31, 2024, and continuing on June 30, 2024, September 30, 2024, and December 31, 2024.
• The options expire on March 4, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a common practice and aligns their interests with shareholders. The vesting schedule incentivizes long-term commitment.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for the vesting period.

Industry Context

Stock options are a common form of compensation for directors, especially in the biotech industry, to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the pharmaceutical and biotechnology industries.
• Companies like Gilead Sciences, Amgen, and Biogen also use stock options as part of their director compensation packages.
• The vesting schedule of these options is fairly standard, with quarterly installments over a year.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with theirs.
• Employees may see this as a standard compensation practice for directors.

Key Dates